Secondary cancer in a survivor of Hodgkin’s lymphoma: A case report and review of the literature

Abstract

Hodgkin’s lymphoma (HL) is one of the most curable malignant diseases in adults. However, HL patients have a higher risk of developing second malignancies compared with the general population. The population of adult cancer survivors is growing, thus, the long-term effects of cancer treatment, including secondary cancer development, have become an increasingly important concern in the field of oncology. The current study presents the case of a female HL survivor who developed two secondary malignancies within 29 years of follow-up. Furthermore, a review of the literature was conducted, which focused on secondary breast and gastrointestinal cancers in HL survivors.

Analysis of Multiple Primary Malignant Neoplasms: A Report from a Tertiary Cancer Centre in South India

“…Hodgkins lymphoma survivors treated with radiotherapy are at an increased risk of developing breast, thyroid, lung and colorectal cancers. Patients treated with combination chemotherapy are more prone to develop secondary leukemias (15,16) . Lung cancer patients are more prone to develop second malignancies which are related to smoking (17) .…”

Bilateral synchronous breast cancer developed as metachronous malignancy after therapy of other primaries

“…Patients treated for Hodgkin's lymphoma (HL), which is often diagnosed at an early age, have a higher risk of developing secondary tumors associated with their treatment (radiotherapy and chemotherapy). After radiotherapy the following are observed with greater frequency: breast cancer, lung cancer, and thyroid cancer [16,17]; and following chemotherapy: leukemia, lung cancer, gastrointestinal cancer, and sarcoma [18]. In 2006 Franklin, et al reported that the application of chemotherapy and radiotherapy in the treatment of HL increases the risk of developing secondary tumors [19].…”

Caecal leiomyoma detected by whole-body MRI in a patient with Hodgkin lymphoma: first case report

“…Several studies, recently reviewed by Lisik-Habib and coworkers (6), assessed or quantified the risk of developing secondary cancers following the successful treatment of HL. However they failed in producing consistent results, possibly due to differences in the number of patients included in the analysis, the characteristics of the study population, the length of the follow-up period, the chemotherapy schedule, the age of HL diagnosis and the dose and volume of irradiation (6). To our knowledge, this is the first case report, according to the scientific literature, of caecal leiomyoma developing after chemotherapy in a HL survivor.…”